Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs

American Journal of Veterinary Research

Volumn 63, Issue 12, 2002, Pages 1718-1723

  Downing, Sue ^a   Chien, May B ^b   Kass, Philip H ^b   Moore, Peter F ^b   London, Cheryl A ^b  

^a Veterinary Cancer Referral Group   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; GENOMIC DNA; ONCOPROTEIN; PARAFFIN; PROTEIN C KIT; UNCLASSIFIED DRUG;

AGED; ANIMAL CELL; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ISOLATION; DOG; EXON; GENE MUTATION; LOGISTIC REGRESSION ANALYSIS; MASTOCYTOMA; METASTASIS; NONHUMAN; ONCOGENE C KIT; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; TANDEM REPEAT; TEACHING HOSPITAL; UNITED STATES; VETERINARY MEDICINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0036910983     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.1718     Document Type: Article

References (47)

1. Macy DW, MacEwen EG. Mast cell tumors. In: Withrow SJ, MacEwen EG, eds. Clinical veterinary oncology. Vol 1. Philadelphia: JB Lippincott Co, 1989;156-166.
2. Abadie JJ, Amardeilh MA, Delverdier ME. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J Am Vet Med Assoc 1999;215:1629-1634.
3. Ayl RD, Couto CG, Hammer AS, et al. Correlation of DNA ploidy to tumor histologic grade, clinical variables, and survival in dogs with mast cell tumors. Vet Pathol 1992;29:386-390.
4. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 1973;14:27-41.
5. Bostock DE, Crocker J, Harris K, et al. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumors. Br J Cancer 1989;59:915-918.
6. Turrel JM, Kitchell BE, Miller LM, et al. Prognostic factors for radiation treatment of mast cell tumors in 85 dogs. J Am Vet Med Assoc 1988;193:936-940.
7. Simoes JP, Schoning P, Butine M. Prognosis of canine mast cell tumors: a comparison of three methods. Vet Pathol 1994;31:637-647.
8. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumors: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
9. Besmer P, Murphy JE, George PC, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family Nature 1986;320:415-421.
10. Austen KF, Boyce JA. Mast cell lineage development and phenotypic regulation. Leuk Res 2001;25:511-518.
11. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994;55:1-95.
12. Zsebo KM, Wypych J, McNiece IK, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990;63:195-201.
13. Tsai M, Takeishi T, Thompson H, et al. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci U S A 1991;88:6382-6386.
14. Nocka K, Buck J, Levi E, et al. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J 1990;10:3287-3294.
15. d mice. Am J Pathol 1987;127:191-198.
16. v mice and their increase by bone marrow transplantation. Blood 1978;52:447-452.
17. d anemic mice. Blood 1979;53:492-497.
18. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand independent activation of c-kit product. J Clin Invest 1993;92:1736-1744.
19. Tsujimura. T, Furitsu T, Morimoto M, et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P815 generated by a point mutation. Blood 1994;83:2619-2626.
20. Tsujimura T, Furitsu T, Morimoto M, et al. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 1995;106:377-385.
21. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:10560-10564.
22. Nagata H, Okada T, Worobec AS, et al. c-hit mutation in a population of patients with mastocytosis. Int Arch Allergy Immunol 1997;113:184-186.
23. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nature Genet 1996;12:312-314.
24. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999;96:1609-1614.
25. Pignon JM, Giraudier S, Duquesnoy P et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997;96:374-376.
26. Worobec AS, Semere T, Nagata H, et al. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998;83:2120-2129.
27. Buttner C, Henz BM, Welker P et al. Identification of activating c-kit mutations in adult- but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998;111:1227-1231.
28. London CA, Kisseberth WC, Galli SJ, et al. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumors. J Comp Pathol 1996;115:399-414.
29. Ma Y, Longley BJ, Wang X, et al. Clustering of activating mutations in c-KIT's juxtamembrane coding region of canine mast cell neoplasms. J Invest Dermatol 1999;112:165-170.
30. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Characterization of an undifferentiated malignancy as a mast cell tumor using mutation analysis in the proto-oncogene c-KIT. J Vet Diagn Invest 2001;13:341-345.
31. Ma Y, Cunningham ME, Wang X, et al. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 1999;274:13399-13402.
32. Giebel LB, Strunk KM, Holmes SA, et al. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. Oncogene 1992;7:2207-2217.
33. Gokkel E, Grossman Z, Ramot B, et al. Structural organization of the murine c-kit proto-oncogene. Oncogene 1992;7:1423-1429.
34. London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-697.
35. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001;25:571-576.
36. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
37. Hibi K, Takahashi T, Sekido Y, et al. Co-expression of the stem cell factor and the c-kit genes in small cell lung cancer. Oncogene 1991;6:2291-2296.
38. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor ST1571. Oncogene 2000;19:3521-3528.
39. Inoue M, Kyo S, Fujita M, et al. Co-expression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994;54:3049-3053.
40. Stanulla M, Welte K, Hadam MR, et al. Coexpression of stem cell factor and its receptor c-kit in human malignant glioma cell lines. Acta Neuropathol 1995;89:158-165.
41. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-795.
42. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-1220.
43. Pietsch T, Nicotra MR, Fraioli R, et al. Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int J Cancer 1998;75:171-175.
44. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233-7239.
45. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med Klin 2002;97(suppl 1):28-30.
46. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-1703.
47. Maki R. Sarcoma, Oncologist 2001;6:333-337.